17AEP-GA, an HSP90 antagonist, is a potent inhibitor of glioblastoma cell proliferation, survival, migration and invasion

Oncology Reports

Volumn 28, Issue 5, 2012, Pages 1903-1909

  Miekus, Katarzyna ^a   Kijowski, Jacek ^a   Sekuła, Małgorzata ^a   Majka, Marcin ^a  

^a JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

Author keywords

Geldanamycins; Glioblastoma; MET receptor; Migration; Proliferation

Indexed keywords

[17 [2 (PYRROLIDIN 1 YL)ETHYL]AMINO 17 DEMETHOXYGELDANAMYCIN]; ANTINEOPLASTIC AGENT; CASPASE 3; LIPOCORTIN 5; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN KINASE B; SCATTER FACTOR; SCATTER FACTOR RECEPTOR; TANESPIMYCIN; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL ASSAY; CELL INVASION; CELL MIGRATION; CELL MOTILITY; CELL STIMULATION; CELL SURVIVAL; CONTROLLED STUDY; DRUG EFFECT; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; GLIOBLASTOMA; HUMAN; HUMAN CELL; MITOSIS INHIBITION; MOLECULAR PATHOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RECEPTOR UPREGULATION; WESTERN BLOTTING;

ANTIBIOTICS, ANTINEOPLASTIC; BENZOQUINONES; BRAIN NEOPLASMS; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; CELL SURVIVAL; GLIOBLASTOMA; HEPATOCYTE GROWTH FACTOR; HSP90 HEAT-SHOCK PROTEINS; HUMANS; LACTAMS, MACROCYCLIC; MITOGEN-ACTIVATED PROTEIN KINASES; NEOPLASM INVASIVENESS; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; PROTO-ONCOGENE PROTEINS C-MET;

EID: 84866437189     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2012.1996     Document Type: Article

References (29)

1. McLendon RE and Halperin EC: Is the long-term survival of patients with intracranial glioblastoma multiforme overstated? Cancer 98: 1745-1748, 2003. (Pubitemid 37238632)
2. Navas-Acién A, Pollán M, Gustavsson P, Floderus B, Plato N and Dosemeci M: Interactive effect of chemical substances and occupational electromagnetic field exposure on the risk of gliomas and meningiomas in Swedish men. Cancer Epidemiol Biomarkers Prev 11: 1678-1683, 2002. (Pubitemid 36020024)
3. Galloway TJ, Indelicato DJ, Amdur RJ, Swanson EL, Smith AA and Marcus RB: Second tumors in pediatric patients treated with radiotherapy to the central nervous system. Am J Clin Oncol 35: 279-283, 2011.
4. Krishnan S, Wade R and Moorman AV: Temporal changes in the incidence and pattern of central nervous system relapses in children with acute lymphoblastic leukaemia treated on four consecutive Medical Research Council trials, 1985-2001. Leukemia 24: 450-459, 2010.
5. Cordier S, Monfort C, Filippini G, et al: Parental exposure to polycyclic aromatic hydrocarbons and the risk of childhood brain tumors: The SEARCH International Childhood Brain Tumor Study. Am J Epidemiol 159: 1109-1116, 2004. (Pubitemid 38747258)
6. Molina JR, Hayashi Y, Stephens C and Georgescu MM: Invasive glioblastoma cells acquire stemness and increased Akt activation. Neoplasia 12: 453-463, 2010.
7. Sauvageot CM, Weatherbee JL, Kesari S, et al: Efficacy of the HSP90 inhibitor 17-AAG in human glioma cell lines and tumorigenic glioma stem cells. Neuro Oncol 11: 109-121, 2009.
8. Abounader R and Laterra J: Scatter factor/hepatocyte growth factor in brain tumor growth and angiogenesis. Neuro Oncol 7: 436-451, 2005. (Pubitemid 41555616)
9. Mazzone M and Comoglio PM: The Met pathway: master switch and drug target in cancer progression. FASEB J. 20: 1611-1621, 2006. (Pubitemid 44943798)
10. Lesko E and Majka M: The biological role of HGF-MET axis in tumor growth and development of metastasis. Front Biosci 13: 1271-1280, 2008. (Pubitemid 351594710)
11. Jiang W, Hiscox S, Matsumoto K and Nakamura T: Hepatocyte growth factor/scatter factor, its molecular, cellular and clinical implications in cancer. Crit Rev Oncol Hematol 29: 209-248, 1999. (Pubitemid 29158969)
12. Weidner KM, Sachs M and Birchmeier W: The Met receptor tyrosine kinase transduces motility, proliferation, and morpho genic signals of scatter factor/hepatocyte growth factor in epithelial cells. J Cell Biol 121: 145-154, 1993. (Pubitemid 23097370)
13. Pratt WB and Toft DO: Regulation of signaling protein function and trafficking by the hsp90/hsp70-based chaperone machinery. Exp Biol Med (Maywood) 228: 111-133, 2003. (Pubitemid 36187918)
14. Maulik G, Kijima T, Ma PC, et al : Modulation of the c-Met/hepatocyte growth factor pathway in small cell lung cancer. Clin Cancer Res 8: 620-627, 2002. (Pubitemid 34193985)
15. Workman P: Altered states: selectively drugging the Hsp90 cancer chaperone. Trends Mol Med 10: 47-51, 2004.
16. Whitesell L, Mimnaugh EG, De Costa B, Myers CE and Neckers LM: Inhibition of heat shock protein HSP90-pp60v-src heteroprotein complex formation by benzoquinone ansamycins: essential role for stress proteins in oncogenic transformation. Proc Natl Acad Sci USA 91: 8324-8328, 1994.
17. Goetz MP, Toft DO, Ames MM and Erlichman C: The Hsp90 chaperone complex as a novel target for cancer therapy. Ann Oncol 14: 1169-1176, 2003. (Pubitemid 37039035)
18. Ochel HJ, Eichhorn K and Gademann G: Geldanamycin: the prototype of a class of antitumor drugs targeting the heat shock protein 90 family of molecular chaperones. Cell Stress Chaperones 6: 105-112, 2001. (Pubitemid 32522216)
19. Lesko E, Gozdzik J, Kijowski J, Jenner B, Wiecha O and Majka M: HSP90 antagonist, geldanamycin, inhibits proliferation, induces apoptosis and blocks migration of rhabdomysoracoma cells in vitro and seeding into bone marrow in vivo. Anticancer Drugs 18: 1173-1181, 2007. (Pubitemid 47480742)
20. Ramanathan RK, Trump DL, Eiseman JL, et al : Phase I pharmacokinetic- pharmacodynamic study of 17-(allylamino)-17-demethoxygeldanamycin (17AAG, NSC 330507), a novel inhibitor of heat shock protein 90, in patients with refractory advanced cancers. Clin Cancer Res 11: 3385-3391, 2005. (Pubitemid 40627891)
21. Xie Q, Thompson R, Hardy K, et al: A highly invasive human glioblastoma pre-clinical model for testing therapeutics. J Transl Med 6: 77, 2008.
22. Zagzag D, Nomura M, Friedlander DR, Blanco CY, Gagner JP, Nomura N and Newcomb EW: Geldanamycin inhibits migration of glioma cells in vitro: a potential role for hypoxia-inducible factor (HIF-1alpha) in glioma cell invasion. J Cell Physiol 196: 394-402, 2003. (Pubitemid 36775888)
23. Lukasiewicz E, Miekus K, Kijowski J, et al : High anti tumor activity against rhabdomyosarcoma cells and low normal cells cytotoxicity of heat shock protein 90 inhibitors, with special emphasis on 17- (2-(pyrrolidin-1-yl)ethyl)- aminno-17-demethoxy-geldanamycin. J Physiol Pharmacol 60: 161-166, 2009.
24. Solit DB, Basso AD, Olshen AB, Scher HI and Rosen N: Inhibition of heat shock protein 90 function down-regulates Akt kinase and sensitizes tumors to Taxol. Cancer Res 63: 2139-2144, 2003. (Pubitemid 36538618)
25. van Engeland M, Nieland LJ, Ramaekers FC, Schutte B and Reutelingsperger CP: Annexin V-affinity assay: a review on an apoptosis detection system based on phosphatidylserine exposure. Cytometry 31: 1-9, 1998. (Pubitemid 28050057)
26. Hardy KM, Yatskievych TA, Konieczka J, Bobbs AS and Antin PB: FGF signalling through RAS/MAPK and PI3K pathways regulates cell movement and gene expression in the chicken primitive streak without affecting E-cadherin expres sion. BMC Dev Biol 11: 20, 2011.
27. Miekus K, Jarocha D, Trzyna E, Majka M: Role of I-TAC-binding receptors CXCR3 and CXCR7 in proliferation, activation of intracellular signaling pathways and migration of various tumor cell lines. Folia Histochem Cytobiol. 48: 104-111, 2010.
28. Xie Q, Gao CF, Shinomiya N, et al: Geldanamycins exquisitely inhibit HGF/SF-mediated tumor cell invasion. Oncogene 24: 3697-3707, 2005. (Pubitemid 40826869)
29. Supko JG, Hickman RL, Grever MR and Malspeis L: Preclinical pharmacologic evaluation of geldanamycin as an antitumor agent. Cancer Chemother Pharmacol 36: 305-315, 1995.